Gene therapy and virotherapy of gastric cancer: Preclinical results and clinical developments

Digestive Diseases

Volumn 22, Issue 4, 2004, Pages 374-379

  Heideman, Daniëlle A M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Gastric cancer; Gastrointestinal cancer; Gene transfer; Oncolytic virus; Stomach cancer; Viral vector

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; B7 ANTIGEN; CARBOXYLESTERASE; CARCINOEMBRYONIC ANTIGEN; CYCLOOXYGENASE 2; CYTOSINE DEAMINASE; ENZYME; ESCHERICHIA COLI PROTEIN; FLUCYTOSINE; FLUOROURACIL; FOLINIC ACID; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPESVIRUS VECTOR; INTERLEUKIN 2; IRINOTECAN; NITROREDUCTASE; ONCOLYTIC VIRUS; ONCOVEX; PARVOVIRUS VECTOR; PRODRUG; PROTEIN P53; THYMIDINE KINASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VIRUS ENZYME; VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; BINDING SITE; BYSTANDER EFFECT; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DELETION MUTANT; ENZYME THERAPY; GASTROINTESTINAL TUMOR; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; GENETIC TRANSCRIPTION; HERPES SIMPLEX VIRUS; HUMAN; INFECTION; INFLUENZA VIRUS; LIVER CANCER; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN MOTIF; REOVIRUS; REVIEW; STOMACH CANCER; TRANSGENE; TREATMENT OUTCOME; TUMOR CELL; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENOME; VIRUS MUTANT; VIRUS REPLICATION; DRUG SCREENING; GENE THERAPY; GENE VECTOR; GENETICS; METHODOLOGY; STOMACH TUMOR; VIRUS;

DRUG EVALUATION, PRECLINICAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; STOMACH NEOPLASMS; TREATMENT OUTCOME; VIRUSES;

EID: 21844470274     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000083601     Document Type: Review

References (49)

1. World Health Report, 1997: Conquering Suffering, Enriching Humanity. Geneva. WHO, 1997.
2. Heideman DAM, Gerritsen WR, Craanen ME: Gene therapy for gastrointestinal tract cancer: A review. Scand J Gastroenterol Suppl 2000;232:93-100.
3. Anderson WF: Prospects for human gene therapy. Science 1984;226:401-409.
4. Losordo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, Cummings N, Schatz RA, Asahara T, Isner JM, Kuntz RE: Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002;105:2012-2018.
5. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, Fischer A, Davies EG, Kuis W, Leiva L, Cavazzana-Calvo M: Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002;346:1185-1193.
6. Springer CJ, Niculescu-Duvaz I: Prodrug-activating systems in suicide gene therapy. J Clin Investig 2000;105:1161-1167.
7. Roth JA, Cristiano RJ: Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst 1997;89:21-39.
8. Heideman DAM, van Beusechem VW, Bloemena E, Snijders PJF, Craanen ME, Offerhaus GJA, Derksen WB, de Bruin M, Witlox MA, Molenaar B, Meijer CJLM, Gerritsen WR: Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK4. J Gene Med 2004;6:317-327.
9. Chung-Faye C, Palmer D, Anderson D, Clark J, Downes M, Baddeley J, Hussain S, Murray PI, Searle P, Seymour L, Harris PA, Ferry D, Kerr DJ: Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: A phase I and pharmacokinetic study of its prodrug, CB1954. Clin Cancer Res 2001;7:2662-2668.
10. Palmer DH, Mautner V, Mirza D, Oliff S, Gerritsen WR, van der Sijp JRM, Hubscher S, Reynolds G, Bonney S, Rajaratnam R, Hull D, Horne M, Ellis J, Mountain A, Hill S, Harris PA, Searle PF, Young LS, James ND, Kerr DJ: Virus-directed enzyme prodrug therapy: Intra-tumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with respectable liver cancer. J Clin Oncol 2004;22:1546-1552.
11. Gilly FN, Beaujard A, Bienvenu J, Trillet Lenoir V, Glehen O, Thouvenot D, Malcus C, Favrot M, Dumontet C, Lombard-Bohas O, Garbit F, Gueugniaud PY, Vignal J, Aymard M, Touraine Moulin F, Roos M, Pavirani A, Courtney M: Gene therapy with Adv-IL-2 in unresectable digestive cancer: Phase I-II study, intermediate report. Hepatogastroenterology 1999;46(suppl):1268-1273.
12. Herrmann F: Cancer gene therapy: Principles, problems, and perspectives. J Mol Med 1995;73:157-163.
13. Vile RG, Russell SJ, Lemoine NR: Cancer gene therapy: Hard lessons and new courses. Gene Ther 2000;7:2-8.
14. Heideman DAM, Snijders PJF, Craanen ME, Bloemena E, Meijer CJLM, Meuwissen SGM, van Beusechem WR, Pinedo HM, Curiel DT, Haisma HJ, Gerritsen WR: Selective gene delivery towards gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Ther 2001;8:342-351.
15. Heideman DAM, van Beusechem VW, Offerhaus GJA, Wickham TJ, Roelvink PW, Craan-en ME, Pinedo HM, Meijer CJLM, Gerritsen WR: Selective gene transfer into primary human gastric tumors using epithelial cell adhesion molecule-targeted adenoviral vectors with ablated native tropism. Hum Gene Ther 2002;13:1677-1685.
16. Magnusson MK, See Hong S, Henning P, Boulanger P, Lindholm L: Genetic retargeting of adenovirus: Novelstrategy employing 'deknobbing' of the fiber. J Virol 2001;75:7280-7289.
17. Yamamoto M, Alemany R, Adachi Y, Grizzle WE, Curiel DT: Characterization of the cyclooxygenase-2 promoter in an adenoviral vector and its application for the mitigation of toxicity in suicide gene therapy of gastrointestinal cancers. Mol Ther 2001;3:385-394.
18. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-376.
19. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR: Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997;57:2559-2563.
20. Fueyo J, Gomez-Manzano C, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, Shi YX, Levin VA, Yung WK, Kyritsis AP: A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19:2-12.
21. Heise C, Hermiston T, Johnson L, Brooks G, Sampson-Johannes A, Williams A, Hawkins L, Kirn D: An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000;6:1134-1139.
22. Martuza RL: Conditionally replicating herpes vectors for cancer therapy. J Clin Invest 2000;105:841-846.
23. Bergmann M, Romirer I, Sachet M, Fleischhacker R, Garcia-Sastre A, Palese P, Wolff K, Pehamberger H, Jakesz R, Muster T: A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res 2001;61:8188-8193.
24. Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ: Newcastle disease virus therapy of human tumor xenografts: Antitumor effects of local or systemic administration. Cancer Lett 2001;172:27-36.
25. Schirrmacher V, Griesbach A, Ahlert T: Antitumor effects of Newcastle disease virus in vivo: Local versus systemic effects. Int J Oncol 2001;18:945-952.
26. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E: Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci USA 2000;97:6803-6808.
27. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW: The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus. EMBO J 1998;17:3351-3362.
28. Wilcox ME, Yang W, Senger D, Rewcastle NB, Morris DG, Brasher PM, Shi ZQ, Johnston RN, Nishikawa S, Lee PW, Forsyth PA: Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 2001;93:903-912.
29. Timiryasova TM, Li J, Chen B, Chong D, Langridge WH, Gridley DS, Fodor I: Antitumor effect of vaccinia virus in glioma model. Oncol Res 1999;11:133-144.
30. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, Moss B, Bartlett DL: Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001;61:8751-8757.
31. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC: Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000;6:821-825.
32. Telerman A, Tuynder M, Dupressoir T, Robaye B, Sigaux F, Shaulian E, Oren M, Rommelaere J, Amson R: A model for tumor suppression using H-1 parvovirus. Proc Natl Acad Sci USA 1993;90:8702-8706.
33. Ponnazhagan S: Parvovirus vectors for cancer gene therapy. Expert Opin Biol Ther 2004;4:53-64.
34. Dupont F: Risk assessment of the use of autonomous parvovirus-based vectors. Curr Gene Ther 2003;3:567-582.
35. Cornelis JJ, Lang SI, Stroh-Dege AY, Balboni G, Dinsart C, Rommelaere J: Cancer gene therapy through autonomous parvovirus-mediated gene transfer. Curr Gene Ther 2004;4:249-261.
36. Oosterhoff D, van Beusechem VW: Conditionally replicating adenoviruses as anticancer agents and ways to improve their efficacy. J Exp Ther Oncol 2004;4:37-57.
37. Varghese S, Rabkin SD: Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002;9:967-978.
38. Takahashi M, Sato T, Sagawa T, Lu Y, Sato Y, Iyama S, Yamada Y, Fukaura J, Takahashi S, Miyanishi K, Yamashita T, Sasaki K, Kogawa K, Hamada H, Kato J, Niitsu Y: E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol Ther 2002;5:627-634.
39. Li Y, Chen Y, Dilley J, Arroyo T, Ko D, Working P, Yu DC: Carcinoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy. Mol Cancer Ther 2003;2:1003-1009.
40. Yamamoto M, Davydova J, Wang M, Siegal GP, Krasnykh V, Vickers SM, Curiel DT: Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology 2003;125:1203-1218.
41. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, Randlev B, Heise C, Uprichard M, Hatfield M, Rome L, Rubin J, Kim D: Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunological and clinical endpoints. Cancer Res 2002;62:6070-6079.
42. GM-CSF. Proc Am Soc Clin Oncol 2003;22:185(abstr 742).
43. Van Beusechem VW, Mastenbroek DC, van den Doel PB, Lamfers ML, Grill J, Wurdinger T, Haisma HJ, Pinedo HM, Gerritsen WR: Conditionally replicative adenovirus expressing a targeting adapter molecule exhibits enhanced oncolytic potency on CAR-deficient tumors. Gene Ther 2003;10:1982-1991.
44. Balague C, Noya F, Alemany R, Chow LT, Curiel DT: Human papillomavirus E6E7-mediated adenovirus cell killing: Selectivity of mutant adenovirus replication in organotypic cultures of human keratinocytes. J Virol 2001;75:7602-7611.
45. Howe JA, Demers GW, Johnson DE, Neugebauer SE, Perry ST, Vaillancourt MT, Faha B: Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy. Mol Ther 2000;2:485-495.
46. Van Beusechem VW, van den Doel PB, Grill J, Pinedo HM, Gerritsen WR: Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. Cancer Res 2002;62:6165-6171.
47. Geoerger B, Vassal G, Opolon P, Dirven CM, Morizet J, Laudani L, Grill J, Giaccone G, Vandertop WP, Gerritsen WR, van Beusechem VW: Oncolytic activity of p53-expressing conditionally replicative adenovirus AdΔ24-p53 against human malignant glioma. Cancer Res 2004;64:5753-5759.
48. Geoerger B, Van Beusechem VW, Opolon P, Morizet J, Laudani L, Lecluse Y, Barrois M, Idema S, Grill J, Gerritsen WR, Vassal G: Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma. J Gene Med 2005, in press.
49. Chu RL, Post DE, Khuri FR, Van Meir EG: Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 2004;10:5299-5312.